AVAI BIO, INC. Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs
AVAI BIO, INC. (AVAI) had Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs of $10.26 thousand as of 2018-09-30, per its 10-Q filed 2018-11-14.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities
us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts · last filed 2018-11-14
- 2018-09-30: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $10.26K.
| Period end | Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs |
|---|---|
| 2018-09-30 | $10.26K 10-Q · filed 2018-11-14 |